The strong anti-kinetoplastid properties of bee propolis : composition and identification of the active agents and their biochemical targets

Ebiloma, Godwin U. and Ichoron, Nahandoo and Siheri, Weam and Watson, David G. and Igoli, John O. and De Koning, Harry P. (2020) The strong anti-kinetoplastid properties of bee propolis : composition and identification of the active agents and their biochemical targets. Molecules (Basel, Switzerland), 25 (21). 5155. ISSN 1420-3049 (https://doi.org/10.3390/molecules25215155)

[thumbnail of Ebiloma-etal-Molecules-2020-The-strong-anti-kinetoplastid-properties-of-bee-propolis]
Preview
 Text. Filename: Ebiloma_etal_Molecules_2020_The_strong_anti_kinetoplastid_properties_of_bee_propolis.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (16MB)| Preview

Abstract

The kinetoplastids are protozoa characterized by the presence of a distinctive organelle, called the kinetoplast, which contains a large amount of DNA (kinetoplast DNA (kDNA)) inside their single mitochondrion. Kinetoplastids of medical and veterinary importance include Trypanosoma spp. (the causative agents of human and animal African Trypanosomiasis and of Chagas disease) and Leishmania spp. (the causative agents of the various forms of leishmaniasis). These neglected diseases affect millions of people across the globe, but drug treatment is hampered by the challenges of toxicity and drug resistance, among others. Propolis (a natural product made by bees) and compounds isolated from it are now being investigated as novel treatments of kinetoplastid infections. The anti-kinetoplastid efficacy of propolis is probably a consequence of its reported activity against kinetoplastid parasites of bees. This article presents a review of the reported anti-kinetoplastid potential of propolis, highlighting its anti-kinetoplastid activity in vitro and in vivo regardless of geographical origin. The mode of action of propolis depends on the organism it is acting on and includes growth inhibition, immunomodulation, macrophage activation, perturbation of the cell membrane architecture, phospholipid disturbances, and mitochondrial targets. This gives ample scope for further investigations toward the rational development of sustainable anti-kinetoplastid drugs.

ORCID iDs

Ebiloma, Godwin U., Ichoron, Nahandoo, Siheri, Weam ORCID logoORCID: https://orcid.org/0000-0001-6569-7281, Watson, David G. ORCID logoORCID: https://orcid.org/0000-0003-1094-7604, Igoli, John O. and De Koning, Harry P.;
CORE (COnnecting REpositories)